PLX
PLX
AMEX · Biotechnology

Protalix Biotherapeutics Inc

$2.33
-0.02 (-0.85%)
As of Jul 4, 2:07 AM ET ·
Financial Highlights (FY 2026)
Revenue
53.87M
Net Income
-6,746,992
Gross Margin
48.8%
Profit Margin
-12.5%
Rev Growth
+3.5%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 48.8% 48.8% 49.5% 49.5%
Operating Margin -10.4% -9.4% 5.5% 5.3%
Profit Margin -12.5% -11.9% 4.3% 3.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 53.87M 52.08M 361.03M 312.42M
Gross Profit 26.30M 25.42M 178.56M 154.52M
Operating Income -5,618,812 -4,888,284 20.00M 16.49M
Net Income -6,746,992 -5,869,785 15.50M 9.93M
Gross Margin 48.8% 48.8% 49.5% 49.5%
Operating Margin -10.4% -9.4% 5.5% 5.3%
Profit Margin -12.5% -11.9% 4.3% 3.2%
Rev Growth +3.5% +3.5% +17.6% +23.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 59.24M 69.52M
Total Equity 91.15M 87.27M
D/E Ratio 0.65 0.80
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -4,123,608 -3,786,783 29.24M 21.92M
Free Cash Flow 6.36M 8.25M